Detailed Information

Cited 0 time in webofscience Cited 0 time in scopus
Metadata Downloads

Mitomycin-C, 5-fluorouracil, and leucovorin as a salvage therapy in patients with metastatic colorectal adenocarcinoma

Authors
Kang, Eun JooChoi, Yoon JiKim, Jung SeonKim, Seung TaePark, Kyong HwaChoi, In KeunOh, Sang ChulSeo, Jae HongShin, Sang WonKim, Jun SukKim, Yeul Hong
Issue Date
Dec-2010
Publisher
WILEY
Keywords
5-FU; leucovorin; mitomycin; refractory colon cancer
Citation
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, v.6, no.4, pp.286 - 291
Indexed
SCIE
SCOPUS
Journal Title
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY
Volume
6
Number
4
Start Page
286
End Page
291
URI
https://scholar.korea.ac.kr/handle/2021.sw.korea/115182
DOI
10.1111/j.1743-7563.2010.01334.x
ISSN
1743-7555
Abstract
Aim: There is no further treatment option for metastatic colon patients who are refractory to standard chemotherapy and to whom novel biological agents are not available. We evaluated the outcomes of mitomycin-C, 5-fluorouracil (5-FU) and leucovorin in patients with metastatic colon cancer previously treated with oxaliplatin/5-FU/leucovorin and irinotecan/5-FU/leucovorin. Methods: We retrospectively analyzed 46 patients who had received mitomycin-C/5FU/leucovorin between March 2008 and December 2009. All patients had failed prior first-line and second-line therapy containing oxaliplatin, irinotecan, and 5-FU. Results: The median age of the patients was 57.0 years (range, 34.0-76.0) and their median Eastern Cooperative Oncology Group performance status was 1 (0-2). A complete or partial response was not observed in any patient and stable disease was observed in 19 patients (41.3%). The median duration of follow up was 29 weeks (range 8-87 weeks). Median progression-free survival was 10 weeks (95% CI 8-12) and median overall survival was 38 weeks (95% CI 32-44). Grade 3 and 4 hematological toxicities included neutropenia in five patients (10.8%) and thrombocytopenia in four patients (8.8%). Grade 3 or 4 non-hematologic toxicities included nausea and vomiting in two patients. There were no treatment-related deaths. Conclusion: The combination regimen of mitomycin-C/5-FU/leucovorin showed marginal activity and tolerable toxicity profiles in heavily pretreated metastatic colorectal cancer patients.
Files in This Item
There are no files associated with this item.
Appears in
Collections
College of Medicine > Department of Medical Science > 1. Journal Articles
Graduate School > Department of Biomedical Sciences > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Park, Kyong Hwa photo

Park, Kyong Hwa
College of Medicine (Department of Medical Science)
Read more

Altmetrics

Total Views & Downloads

BROWSE